收费全文 | 3237970篇 |
免费 | 270463篇 |
国内免费 | 13746篇 |
耳鼻咽喉 | 44259篇 |
儿科学 | 103828篇 |
妇产科学 | 82895篇 |
基础医学 | 521712篇 |
口腔科学 | 86990篇 |
临床医学 | 291488篇 |
内科学 | 564333篇 |
皮肤病学 | 88327篇 |
神经病学 | 278976篇 |
特种医学 | 127348篇 |
外国民族医学 | 329篇 |
外科学 | 501170篇 |
综合类 | 100648篇 |
现状与发展 | 23篇 |
一般理论 | 2263篇 |
预防医学 | 274342篇 |
眼科学 | 73848篇 |
药学 | 220337篇 |
23篇 | |
中国医学 | 9314篇 |
肿瘤学 | 149726篇 |
2021年 | 54828篇 |
2020年 | 35000篇 |
2019年 | 57928篇 |
2018年 | 70740篇 |
2017年 | 53985篇 |
2016年 | 59560篇 |
2015年 | 73703篇 |
2014年 | 107867篇 |
2013年 | 173109篇 |
2012年 | 86651篇 |
2011年 | 86170篇 |
2010年 | 115266篇 |
2009年 | 119984篇 |
2008年 | 73252篇 |
2007年 | 75398篇 |
2006年 | 86562篇 |
2005年 | 81850篇 |
2004年 | 84183篇 |
2003年 | 75205篇 |
2002年 | 64966篇 |
2001年 | 94401篇 |
2000年 | 86935篇 |
1999年 | 88638篇 |
1998年 | 64297篇 |
1997年 | 62351篇 |
1996年 | 60116篇 |
1995年 | 55663篇 |
1994年 | 49934篇 |
1993年 | 46502篇 |
1992年 | 62337篇 |
1991年 | 59450篇 |
1990年 | 56554篇 |
1989年 | 55930篇 |
1988年 | 51592篇 |
1987年 | 51006篇 |
1986年 | 48115篇 |
1985年 | 48632篇 |
1984年 | 45265篇 |
1983年 | 41545篇 |
1982年 | 40681篇 |
1981年 | 38490篇 |
1980年 | 36195篇 |
1979年 | 37047篇 |
1978年 | 33745篇 |
1977年 | 30953篇 |
1976年 | 28454篇 |
1975年 | 26798篇 |
1974年 | 27568篇 |
1973年 | 26525篇 |
1972年 | 24637篇 |
Background
We have recently shown that human epididymis protein 4 (HE4) levels correlate with the severity of cystic fibrosis (CF) lung disease. However, there are no data on how HE4 levels alter in patients receiving CFTR modulating therapy.Methods
In this retrospective clinical study, 3 independent CF patient cohorts (US-American: 29, Australian: 12 and Irish: 19 cases) were enrolled carrying at least one Class III CFTR CF-causing mutation (p.Gly551Asp) and being treated with CFTR potentiator ivacaftor. Plasma HE4 was measured by immunoassay before treatment (baseline) and 1–6?months after commencement of ivacaftor, and were correlated with FEV1 (% predicted), sweat chloride, C-reactive protein (CRP) and body mass index (BMI).Results
After 1?month of therapy, HE4 levels were significantly lower than at baseline and remained decreased up to 6?months. A significant inverse correlation between absolute and delta values of HE4 and FEV1 (r?=??0.5376; P?<?.001 and r?=??0.3285; P?<?.001), was retrospectively observed in pooled groups, including an independent association of HE4 with FEV1 by multiple regression analysis (β?=??0.57, P?=?.019). Substantial area under the receiver operating characteristic curve (ROC-AUC) value was determined for HE4 when 7% mean change of FEV1 (0.722 [95% CI 0.581–0.863]; P?=?.029) were used as classifier, especially in the first 2?months of treatment (0.806 [95% CI 0.665–0.947]; P?<?.001).Conclusions
This study shows that plasma HE4 levels inversely correlate with lung function improvement in CF patients receiving ivacaftor. Overall, this potential biomarker may be of value for routine clinical and laboratory follow-up of CFTR modulating therapy. 相似文献Background
Chronic limb-threatening ischemia (CLTI), defined as ischemic rest pain or tissue loss secondary to arterial insufficiency, is caused by multilevel arterial disease with frequent, severe infrageniculate disease. The rise in CLTI is in part the result of increasing worldwide prevalence of diabetes, renal insufficiency, and advanced aging of the population. The aim of this study was to compare a bypass-first with an endovascular-first revascularization strategy in patients with CLTI due to infrageniculate arterial disease.Methods
We reviewed the American College of Surgeons National Surgical Quality Improvement Program targeted lower extremity revascularization database from 2012 to 2015 to identify patients with CLTI and isolated infrageniculate arterial disease who underwent primary infrageniculate bypass or endovascular intervention. We excluded patients with a history of ipsilateral revascularization and proximal interventions. The end points were major adverse limb event (MALE), major adverse cardiovascular event (MACE), amputation at 30 days, reintervention, patency, and mortality. Multivariable logistic regression was used to determine the association of a bypass-first or an endovascular-first intervention with outcomes.Results
There were 1355 CLTI patients undergoing first-time revascularization to the infrageniculate arteries (821 endovascular-first revascularizations and 534 bypass-first revascularizations) identified. There was no significant difference in adjusted rate of 30-day MALE in the bypass-first vs endovascular-first revascularization cohort (9% vs 11.2%; odds ratio [OR], 0.73; 95% confidence interval [CI], 0.50-1.08). However, the incidence of transtibial or proximal amputation was lower in the bypass-first cohort (4.3% vs 7.4%; OR, 0.60; CI, 0.36-0.98). Patients with bypass-first revascularization had higher wound complication rates (9.7% vs 3.7%; OR, 2.75; CI, 1.71-4.42) compared with patients in the endovascular-first cohort. Compared with the endovascular-first cohort, the incidence of 30-day MACE was significantly higher in bypass-first patients (6.9% vs 2.6%; adjusted OR, 3.88; CI, 2.18-6.88), and 30-day mortality rates were 3.23% vs 1.8% (adjusted OR, 2.77; CI, 1.26-6.11). There was no difference in 30-day untreated loss of patency, reintervention of treated arterial segment, readmissions, and reoperations between the two cohorts. In subgroup analysis after exclusion of dialysis patients, there was also no significant difference in MALE or amputation between the bypass-first and endovascular-first cohorts.Conclusions
CLTI patients with isolated infrageniculate arterial disease treated by a bypass-first approach have a significantly lower 30-day amputation. However, this benefit was not observed when dialysis patients were excluded. The bypass-first cohort had a higher incidence of MACE compared with an endovascular-first strategy. These results reaffirm the need for randomized controlled trials, such as the Bypass versus Angioplasty in Severe Ischaemia of the Leg (BASIL-2) trial and Best Endovascular vs Best Surgical Therapy in Patients with Critical Limb Ischemia (BEST-CLI), to provide level 1 evidence for the role of endovascular-first vs bypass-first revascularization strategies in the treatment of this population of challenging patients. 相似文献Robotic approaches have been steadily replacing laparoscopic approaches in metabolic and bariatric surgeries (MBS); however, their superiority has not been rigorously evaluated. The main goal of the study was to evaluate the 5-year utilization trends of robotic MBS and to compare to laparoscopic outcomes.
MethodsRetrospective analysis of 2015–2019 MBSAQIP data. Kruskal-Wallis test/Wilcoxon and Fisher’s exact/chi-square were used to compare continuous and categorical variables, respectively. Generalized linear models were used to compare surgery outcomes.
ResultsThe use of robotic MBS increased from 6.2% in 2015 to 13.5% in 2019 (N= 775,258). Robotic MBS patients had significantly higher age, BMI, and likelihood of 12 diseases compared to laparoscopic patients. After adjustment, robotic MBS patients showed higher 30-day interventions and 30-day readmissions alongside longer surgery time (26–38 min).
ConclusionRobotic MBS shows higher intervention and readmission even after controlling for cofounding variables.
Graphical Abstract 相似文献